Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 172 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infections, Clostridium Difficile Clear all
Completed Phase 2 Interventional Results available

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

NCT04247542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Ibezapolstat, Vancomycin
Drug
Lead sponsor
Acurx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
29
States / cities
Scottsdale, Arizona • Apple Valley, California • Camarillo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 8, 2026, 4:47 PM EDT
Completed No phase listed Observational

Response of Clostridium Difficile Infection to Metronidazole Therapy

NCT00304369
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Metronidazole
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

NCT00350298
View directory record Official record
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods

NCT02375477
View directory record Official record
Conditions
Bacterial Infection, Clostridium Difficile
Interventions
Educational Intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine Efficacy Trial

NCT03090191
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
17,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
220
States / cities
Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Completed No phase listed Observational Results available

Molecular Epidemiology of Clostridium Difficile Infections in Children

NCT01957761
View directory record Official record
Conditions
Clostridium Difficile Infections
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 8, 2026, 4:47 PM EDT
Recruiting Phase 1 Interventional

Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection

NCT06370884
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Interventions
IMT
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 8, 2026, 4:47 PM EDT
Completed No phase listed Observational

Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea

NCT00304876
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 8, 2026, 4:47 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant for Primary CDI

NCT03795233
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
Biological · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 8, 2026, 4:47 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

NCT00466635
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
Interventions
GT267-004 (tolevamer potassium sodium)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Modesto, California • Honolulu, Hawaii • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 4 Interventional

Animal-Assisted Visitation Program Chlorhexidine Trial

NCT04171817
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
Interventions
Chlorhexidine
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
3 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 8, 2026, 4:47 PM EDT
Completed No phase listed Observational

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

NCT04317963
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Bezlotoxumab, Standard CDI treatment
Biological · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Terminated Phase 4 Interventional Results available

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

NCT04626947
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Interventions
Bezlotoxumab
Biological
Lead sponsor
David Binion, MD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 8, 2026, 4:47 PM EDT
Completed No phase listed Observational

Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection

NCT02326636
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbial Transplantation
Biological
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT03788434
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions
VE303, Placebo
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Recruiting Not applicable Interventional

Fecal Microbiota Transplantation for C Diff Infection

NCT01905709
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Human fecal matter
Biological
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 8, 2026, 4:47 PM EDT
Completed No phase listed Observational

Observational Study of C. Diff in Post-Transplant Patients

NCT02747017
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Minneapolis, Minnesota • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection

NCT00304356
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions
Nitazoxanide
Drug
Lead sponsor
Daniel M. Musher MD
Federal
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

NCT03183141
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
SER-109
Biological
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
97
States / cities
Dothan, Alabama • Sun City West, Arizona • Mather, California + 84 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

NCT02218372
View directory record Official record
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Interventions
Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid, Vancomycin capsules
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
Up to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Orange, California • Chicago, Illinois • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Study of CB-183,315 in Participants With Clostridium Difficile Infection

NCT01085591
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
CB-183,315, Placebo, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 8, 2026, 4:47 PM EDT
Terminated Phase 2 Interventional Results available

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

NCT03973697
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection
Interventions
Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 8, 2026, 4:47 PM EDT
Terminated Not applicable Interventional

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

NCT01441271
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Ileal diversion and lavage, total abdominal colectomy
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 8, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

NCT03183128
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-109, Placebo
Biological · Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
51
States / cities
North Little Rock, Arkansas • Mather, California • Mountain View, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 8, 2026, 4:47 PM EDT